BioPharma merger with BLS to create ‘global leader’ in R&D services

North American CRO BioPharma has acquired fellow contract research group Bioanalytical Laboratory Services (BLS) to “further expand and fortify its analytical services and become a global leader in clinical research.”

BioPharma, which has bases in the U.S. and Canada and a HQ in Toronto, has bought out Canadian CRO BLS for an undisclosed fee in order to get its hands on the company’s bioanalytical research center.

This hub specializes in complex method development, method validation and the analysis of biological samples for pre-clinical and early-stage clinical drug trials.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Its assets will now be combined with BioPharma’s existing Bioanalytical Lab as the two look to become a bigger player in this research area.

Renzo DiCarlo, CEO at BioPharma Services, said: "We are very proud to combine the best of BioPharma’s existing bioanalytical lab with the best of BLS. Under the scientific leadership of [BLS’ lab director Dr. Nicola Hughes], the expanded lab at BioPharma will be able to immediately offer challenging and complex new assays while strengthening our Scientific R&D team. This is just one of a list of benefits associated with merging the assets of two great labs at BioPharma.”

Effective immediately, Dr. Hughes will be appointed to the BioPharma executive team as the VP of lab operations, according to the company’s statement.

“I am extremely excited about my team joining the BioPharma team and believe together, by offering scientific excellence, high quality assays and our commitment to providing exceptional service to our clients, we are ideally suited for the early stage research market,” Dr. Hughes said.

- check out the release

Related Articles:
Frontage doubles its bioanalytics space
Quintiles beefs up in bioanalytics ahead of Quest partnership
After Warnex buy, Biotrial jumps into bioanalytics

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.